Celsion Appoints Director of Communications and Strategic Initiatives
COLUMBIA, Md., July 28 /PRNewswire-FirstCall/ -- Celsion Corporation (NASDAQ:CLSN) , a biotechnology drug development company that is leveraging its heat sensitive liposomal technology platform to encapsulate and deliver high concentrations of proven chemotherapeutics, today announced the appointment of Sid Taubenfeld as Director of Communications and Strategic Initiatives, effective immediately.
"We are pleased to have Sid join the Celsion management team as we enter the second half of what should prove to be an exciting year," said Michael Tardugno, President and Chief Executive Officer of Celsion. "Sid's strong background in the financial industry, deep understanding of Celsion's clinical programs and prior experience as a pharmacist make him an ideal candidate to direct and manage our strategic initiatives and communications."
For the past 11 years, Mr. Taubenfeld has served as a buy-side healthcare equities research analyst at three Wall Street funds, including Balyasny Asset Management (BAM), RH Capital and most recently PAW Partners. His area of coverage focuses on major and specialty pharmaceutical companies as well as the biotechnology sector.
Mr. Taubenfeld is a registered pharmacist and started his career as a clinical pharmacist in the area of critical medicine and Total Parenteral Nutrition. He also has managed the pharmacy at Bellevue Hospital in New York and served as a consultant to Infusion Technology Services, a home healthcare company, focusing on clinical operations.
Celsion is dedicated to the development and commercialization of innovative oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat-activated drug delivery systems. Celsion has licensed ThermoDox(R) to Yakult-Honsha for the Japanese market and has a partnership agreement with Phillips Medical to jointly develop its heat activated liposomal technology in combination with high intensity focused ultrasound to treat difficult cancers. Celsion has research, license, or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, Cleveland Clinic, and the North Shore Long Island Jewish Health System.
For more information on Celsion, visit our website: http://www.celsion.com/.
Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.
The Trout Group, LLC
Source: Celsion Corporation
CONTACT: Marcy Nanus, The Trout Group, LLC, +1-646-378-2927,